abrdn plc Acquires Shares of 21,697 Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)

abrdn plc purchased a new stake in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 21,697 shares of the company’s stock, valued at approximately $209,000.

Several other institutional investors and hedge funds have also bought and sold shares of FUSN. Federated Hermes Inc. raised its position in shares of Fusion Pharmaceuticals by 1.9% in the 4th quarter. Federated Hermes Inc. now owns 10,886,153 shares of the company’s stock valued at $104,616,000 after buying an additional 202,364 shares in the last quarter. HealthInvest Partners AB acquired a new position in Fusion Pharmaceuticals during the fourth quarter valued at approximately $1,201,000. Avidity Partners Management LP lifted its stake in Fusion Pharmaceuticals by 1.4% during the third quarter. Avidity Partners Management LP now owns 5,781,850 shares of the company’s stock worth $15,033,000 after purchasing an additional 81,850 shares during the last quarter. Yarbrough Capital LLC acquired a new stake in shares of Fusion Pharmaceuticals in the 4th quarter valued at $739,000. Finally, Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Fusion Pharmaceuticals in the 4th quarter valued at $299,000. Institutional investors own 72.85% of the company’s stock.

Fusion Pharmaceuticals Price Performance

Shares of NASDAQ:FUSN opened at $21.43 on Wednesday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 15.01 and a current ratio of 15.01. Fusion Pharmaceuticals Inc. has a 52 week low of $2.31 and a 52 week high of $21.55. The firm has a market cap of $1.82 billion, a PE ratio of -14.58 and a beta of -0.73. The firm’s fifty day moving average is $17.40 and its 200-day moving average is $10.80.

Fusion Pharmaceuticals (NASDAQ:FUSN) last announced its earnings results on Wednesday, March 20th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative return on equity of 46.59% and a negative net margin of 4,136.55%. Sell-side analysts predict that Fusion Pharmaceuticals Inc. will post -1.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on FUSN shares. SVB Leerink reissued a “market perform” rating and set a $21.00 price target (up previously from $17.00) on shares of Fusion Pharmaceuticals in a report on Tuesday, March 19th. Royal Bank of Canada reissued a “sector perform” rating and issued a $21.00 target price (up previously from $16.00) on shares of Fusion Pharmaceuticals in a report on Wednesday, March 20th. Truist Financial reaffirmed a “hold” rating and set a $21.00 price target (up from $11.00) on shares of Fusion Pharmaceuticals in a report on Tuesday, March 19th. Raymond James reissued a “market perform” rating on shares of Fusion Pharmaceuticals in a research note on Tuesday, March 19th. Finally, Bloom Burton lowered shares of Fusion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, March 20th. Thirteen investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $20.25.

About Fusion Pharmaceuticals

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.